FDA Approves Zepbound: Eli Lilly's New Weight Loss Medication

The FDA has approved Zepbound, a new weight loss medication developed by Eli Lilly. Zepbound is a brand name for tirzepatide, which has been proven to be highly effective for weight loss by reducing appetite and improving the body's metabolism. It will be available by the end of the year and is intended to be used in combination with a reduced-calorie diet and increased physical activity. The drug will be approved for individuals with a body mass index (BMI) of 30 or greater, or a BMI of 27 with at least one weight-related condition. The price without insurance is expected to be $1,059. Zepbound is similar to other medications like Mounjaro, Ozempic, and Wegovy, which have gained popularity for weight loss.